Valiant Laboratories Announces 5th AGM on Sep 28, 2026, Releases Annual Report FY26
Valiant Laboratories will hold its 5th AGM on September 28, 2026. The company reported FY26 revenue of ₹217.04 crore, a 62.7% increase, and returned to profitability with PAT of ₹5.55 crore. Commercial operations began at subsidiary VASPL in November 2025. A rights issue in August 2025 raised ₹81.47 crore, leading to a debt-free status.
The AGM date, release of the annual report with strong financial performance, commencement of a new subsidiary's operations, and achieving a debt-free status are material events that will significantly impact investor perception and the company's future outlook.
The announcement details a return to profitability, significant revenue growth, successful commencement of a subsidiary's operations, and a strengthened financial position with zero debt, all of which are positive indicators for the company.
Valiant Laboratories Limited has announced the Notice of its 5th Annual General Meeting (AGM) along with the Annual Report for the Financial Year 2025-26. The AGM is scheduled to be held on Monday, September 28, 2026, at 11:30 a.m. IST, through Video Conferencing / Other Audio Visual Means.
In compliance with MCA and SEBI circulars, the Notice of the AGM and the Annual Report have been sent electronically to members whose email addresses were registered as of Friday, August 28, 2026. The Annual Report for FY2025-26 highlights a significant turnaround for the company, with revenue from operations growing by 62.7% to ₹217.04 crore. The company returned to profitability, posting a profit after tax (PAT) of ₹5.55 crore for FY26, a substantial improvement from a loss of ₹2.15 crore in the previous year. EBITDA margins also saw a recovery, rising to 4.64% from 0.56% in the prior year.
The company also reported the commencement of commercial operations at its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), in November 2025. VASPL's facility in Saykha, Gujarat, is focused on specialty chemicals, including Acetic Anhydride, a key input for Paracetamol production. This backward integration strategy, along with sourcing key starting materials from within the Aarti Group, strengthens supply continuity and reduces import volatility.
Valiant Laboratories has also strengthened its financial position by completing a Rights Issue in August 2025, which raised ₹81.47 crore. The majority of these funds were used to fully repay outstanding term borrowings, resulting in a debt-equity ratio of NIL as of FY26, down from 0.25 in the previous year. The company is also working towards WHO-GMP compliance by next year to support entry into semi-regulated export markets.
A plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.